Table 1.

Prevalence at enrollment and incidence rates of cervical HPV infection by genotype and number of coinfections

GenotypePrevalence at entry, n (%) *Woman-months of follow-up All incident infectionsNo coinfection One or more coinfection
No. incident infections §Incidence rate per 1,000 woman-months (95% CI)No. incident infections Incidence rate per 1,000 woman-months (95% CI)No. incident infections Incidence rate per 1,000 woman-months (95% CI)
Any HPV **603 (25.6)907511813.00 (10.76–15.57)
HR-HPV ††493 (20.9)10150949.26 (7.48–11.33)454.43 (3.23–5.93)494.83 (3.57–6.38)
    16110 (4.7)13596241.77 (1.13–2.63)30.22 (0.05–0.64)211.54 (0.96–2.36)
    1840 (1.7)1406870.50 (0.20–1.03)20.14 (0.02–0.51)50.36 (0.12–0.83)
    262 (0.1)1433020.14 (0.02–0.50)00.00 (0.00–0.26)20.14 (0.02–0.50)
    3143 (1.8)13955241.72 (1.10–2.56)70.50 (0.20–1.03)171.22 (0.71–1.95)
    3313 (0.6)1425750.35 (0.11–0.82)10.07 (0.00–0.39)40.28 (0.08–0.72)
    3519 (0.8)1422560.42 (0.15–0.92)10.07 (0.00–0.39)50.35 (0.11–0.82)
    3950 (2.1)13999171.21 (0.71–1.94)30.21 (0.04–0.63)141.00 (0.55–1.68)
    4525 (1.1)14217120.84 (0.44–1.47)30.21 (0.04–0.62)90.63 (0.29–1.20)
    5155 (2.3)13943171.22 (0.71–1.95)20.14 (0.02–0.52)151.08 (0.60–1.77)
    5283 (3.5)13388272.02 (1.33–2.93)50.37 (0.12–0.87)221.64 (1.03–2.49)
    5357 (2.4)13903221.58 (0.99–2.40)20.14 (0.02–0.52)201.44 (0.88–2.22)
    5636 (1.5)14043151.07 (0.60–1.76)40.28 (0.08–0.73)110.78 (0.39–1.40)
    5844 (1.9)1391090.65 (0.30–1.23)40.29 (0.08–0.74)50.36 (0.12–0.84)
    5936 (1.5)14069151.07 (0.60–1.76)30.21 (0.04–0.62)120.85 (0.44–1.49)
    6644 (1.9)14062141.00 (0.54–1.67)40.28 (0.08–0.73)100.71 (0.34–1.31)
    6823 (1.0)14168100.71 (0.34–1.30)50.35 (0.11–0.82)50.35 (0.11–0.82)
    7014 (0.6)1421730.21 (0.04–0.62)00.00 (0.00–0.26)30.21 (0.04–0.62)
    7316 (0.7)1424590.63 (0.29–1.20)10.07 (0.00–0.39)80.56 (0.24–1.11)
    8214 (0.6)1423350.35 (0.11–0.82)10.07 (0.00–0.39)40.28 (0.08–0.72)
LR HPV ‡‡175 (7.4)11893988.24 (6.69–10.04)453.78 (2.76–5.06)847.06 (5.63–8.74)
Low risk
    642 (1.8)14195140.99 (0.54–1.65)20.14 (0.02–0.51)120.85 (0.44–1.48)
    115 (0.2)1429350.35 (0.11–0.82)10.07 (0.00–0.39)40.28 (0.08–0.72)
    404 (0.2)1436310.07 (0.00–0.39)00.00 (0.00–0.26)10.07 (0.00–0.39)
    4225 (1.1)14104151.06 (0.60–1.75)30.21 (0.04–0.62)120.85 (0.44–1.49)
    5435 (1.5)14098281.99 (1.32–2.87)70.50 (0.20–1.02)211.49 (0.92–2.28)
    6138 (1.6)13944251.79 (1.16–2.65)70.50 (0.20–1.03)181.29 (0.77–2.04)
    728 (0.3)1430130.21 (0.04–0.61)20.14 (0.02–0.51)10.07 (0.00–0.39)
    8115 (0.6)14183110.78 (0.39–1.39)20.14 (0.02–0.51)90.63 (0.29–1.20)
    8940 (1.7)13907292.09 (1.40–2.99)40.29 (0.08–0.74)251.80 (1.16–2.65)
Undetermined risk
    341 (0.0)1435820.14 (0.02–0.50)10.07 (0.00–0.39)10.07 (0.00–0.39)
    4417 (0.7)14184171.20 (0.70–1.92)30.21 (0.04–0.62)140.99 (0.54–1.66)
    6255 (2.3)13862251.80 (1.17–2.66)80.58 (0.25–1.14)171.23 (0.71–1.96)
    6722 (0.9)14224110.77 (0.39–1.38)10.07 (0.00–0.39)100.70 (0.34–1.29)
    716 (0.3)1431220.14 (0.02–0.50)10.07 (0.00–0.39)10.07 (0.00–0.39)
    8323 (1.0)14191120.85 (0.44–1.48)30.21 (0.04–0.62)90.63 (0.29–1.20)
    8433 (1.4)14063332.35 (1.62–3.30)50.36 (0.12–0.83)281.99 (1.32–2.88)
Species §§
    164 (2.7)13672392.85 (2.03–3.90)70.51 (0.21–1.05)322.34 (1.60–3.30)
    3152 (6.5)12925896.89 (5.53–8.47)272.09 (1.38–3.04)624.80 (3.68–6.15)
    571 (3.0)13798231.67 (1.06–2.50)30.22 (0.04–0.64)201.45 (0.89–2.24)
    6127 (5.4)13376402.99 (2.14–4.07)100.75 (0.36–1.37)302.24 (1.51–3.20)
    7168 (7.1)13058523.98 (2.97–5.22)141.07 (0.59–1.80)382.91 (2.06–3.99)
    9290 (12.3)11758635.36 (4.12–6.86)201.70 (1.04–2.63)433.66 (2.65–4.93)
    1064 (2.7)13947322.29 (1.57–3.24)60.43 (0.16–0.94)261.86 (1.22–2.73)
  • * Prevalence among the 2,356 women who completed at least one clinical visit.

  • Months of follow-up for subjects at risk of acquiring an infection.

  • Other HPV genotypes detected at time of acquisition of the index infection.

  • § Overall number of genotype-specific incident infections: 476, including HR-HPV, 243 and LR-HPV, 233.

  • Number of genotype-specific incident infections with no coinfection: 101, including HR-HPV, 51 and LR-HPV, 50.

  • Number of genotype-specific incident infections with 1+ coinfection: 375, including HR-HPV, 192 and LR-HPV, 183.

  • ** Acquisition of any HPV type after an HPV-negative result. For example, if a woman tested positive for HPV-16 at her second clinical visit and for HPV-81 at her third visit, this would not count as an acquisition event for any HPV analysis.

  • †† Acquisition of an HR-HPV type after an HR-HPV–negative result. For example, if a woman tested positive for HPV-16 at her second clinical visit and for HPV-18 at her third visit, this would not count as an acquisition event for HR-HPV analysis.

  • ‡‡ Acquisition of a LR-HPV type after an LR-HPV–negative result. Includes genotypes of undetermined oncogenic risk.

  • §§ α-Papillomavirus species: species 1 comprises types 42 and 89; species 3 comprises types 61, 62, 72, 81, 83, and 84; species 5 comprises types 26, 51, and 82; species 6 comprises types 53, 56, and 66; species 7 comprises types 18, 39, 45, 59, 68, and 70; species 9 comprises types 16, 31, 33, 35, 52, 58, and 67; and species 10 comprises types 6, 11, and 44.